Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger ...

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

Natural "off switch" could slow or even reverse the growth of aggressive tumors.

Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different ...

Alternative RNA splicing is like a movie editor cutting ... Further studies will refine ASO-based therapies and explore their delivery to tumors. However, preliminary data suggest that ASOs ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

whereas the search term “RNAi AND TGS NOT PTGS” only returned 25 hits (as of 18.10.2024). Hence, most published studies are concerned with the investigation of effects resulting from the inhibition of ...

And then with regard to other types of therapies like siRNA, ASO, RNA editing, our key focus is on ensuring that we allow CRISPR or use CRISPR to do things that others cannot, that those cannot do.

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

And then with regard to other types of therapies like siRNA, ASO, RNA editing, our key focus is on ensuring that we allow CRISPR or use CRISPR to do things that others cannot, that those cannot do.